Pasithea Therapeutics Corp. (KTTA) Stock Forecast
KTTA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $3.00 average of analyst targets
- Upside to target
- +614.3% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.21
- 52-week range
- $0.29 – $1.47
KTTA analyst ratings
1 analystsNumber of analysts at each rating.
KTTA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KTTA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.21 | — | — | 1 |
| Current fiscal year (2026) | −$0.76 | −$0.76 | −$0.76 | −$2.91 | +73.9% | 1 |
| Next fiscal year (2027) | −$0.46 | −$0.46 | −$0.46 | −$0.76 | +39.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KTTA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
KTTA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KTTA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.48 | −$0.21 | −$0.21 | −$0.21 | −$0.21 | −56.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.86 | −$0.76 | −$0.76 | −$0.76 | −$0.76 | −59.1% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.10 | −$1.01 | −$1.01 | −$1.01 | −$0.46 | −78.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KTTA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KTTA beat in 3 of 6.
What analysts expect from KTTA
1 analysts cover Pasithea Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.00, 614.3% above the latest close of $0.42. Analysts expect earnings of −$0.76 per share for 2026, +73.9% from a year earlier. For 2027 the average estimate is −$0.46 per share. Pasithea Therapeutics beat the EPS estimate in 3 of the last 6 quarters.
Related: KTTA income statement, KTTA key metrics, KTTA chart. See the KTTA stock overview for the latest quote and news.
KTTA forecast FAQ
What is Pasithea Therapeutics's price target?
The average analyst price target for Pasithea Therapeutics is $3.00, 614.3% above the latest close of $0.42.
Is Pasithea Therapeutics a buy, hold or sell?
Of 1 analysts covering Pasithea Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Pasithea Therapeutics's EPS forecast?
Analysts forecast −$0.76 per share for 2026 (range −$0.76 to −$0.76); for 2027 the estimate is −$0.46.
When does Pasithea Therapeutics report earnings?
Pasithea Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.21.
Does Pasithea Therapeutics usually beat earnings estimates?
Pasithea Therapeutics reported EPS at or above the analyst estimate in 3 of the last 6 quarters.